The post hoc analysis of the DUAL VII Japan study found that switching from low‐dose premixed insulin to IDegLira in patients with uncontrolled type 2 diabetes (n = 39, mean baseline HbA1c 8.26% [67 mmol/mol]) resulted in improved HbA1c and generated weight loss.21 The gene discussed is INS; the disease is type 2 diabetes mellitus.